Significant Progress Made as Numinus-Sponsored PRIME Study on Psilocybin-Assisted Psychotherapy for Opioid, Stimulant and/or Alcohol Use Disorders Enters Pre-Implementation Stage
Numinus Wellness (OTC:LKYSD) and Syreon Corporation, a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. The study will contribute to a growing body of research to inform larger randomized controlled trials for these indications. The study will take place in Vancouver and will enroll 30 individuals with opioid, stimulant and/or alcohol use disorders. Syreon is leading the trial as Clinical Research Organization (CRO) with Numinus as the trial sponsor.
Share this article
Share this article
ENGLEWOOD, Colo., March 3, 2021 /PRNewswire/ Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today reported annual financial results for the year ended December 31, 2020 and provided a corporate overview / business update.
Mr. Michael Macaluso, President and CEO, noted, The FDA has recently responded to our requests to expand our IV and Inhalation Covid-19 studies, utilizing Ampion, by recommending we conduct a randomized, double-blinded, placebo-controlled Phase II trial in each. They also indicated that their recommended trial design for both will allow for an effective and efficient review of data results, determine the safety and statistical significance and effectiveness of Ampion in comparison to Standard of Care, all of which are necessary for the FDA to objectively determine that the known and potential benefit
Canntab Therapeutics Limited: Canntab Fulfills 80% of Its Contract with MediPharm Labs Corp.
Company or
Canntab ), the leading innovator in cannabinoid and terpene blends in hard pill form for medical and therapeutic applications, is pleased to announce that it has completed its 2
nd (second) delivery of (2) (two) additional SKU s ordered by MediPharm Labs Corp ( MediPharm Labs ) (TSX: LABS) (OTCQX: MEDIF) including 12.5mg CBD caplets (hard tablets in the shape of capsules) and 25mg CBD caplets for approximately $550,000.00. Canntab has now fulfilled 80% of the purchase amount contracted under the wholesale table purchase agreement entered into by the Company and MediPharm Labs in June, 2020.
Quartesian Extends Growth Record in 2020 yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
FDA Approves Investigational New Drug (IND) for Neuroendocrine Tumors from Molecular Targeting Technologies, Inc.
March 2, 2021 GMT
WEST CHESTER, Pa. (BUSINESS WIRE) Mar 2, 2021
Molecular Targeting Technologies, Inc. (MTTI), a clinical stage radiopharmaceutical therapy company focused on therapies for rare diseases, announced today the approval of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). It enables a Phase I clinical study of the Safety and Dosimetry of its lead product, EBTATE ( 177 Lu-DOTA-EB-TATE), in patients with neuroendocrine tumors (NET).